AG2R LA Mondiale Gestion D Actifs Buys Shares of 6,559 Cencora, Inc. $COR

AG2R LA Mondiale Gestion D Actifs bought a new stake in Cencora, Inc. (NYSE:COR) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 6,559 shares of the company’s stock, valued at approximately $1,910,000.

Other institutional investors also recently bought and sold shares of the company. Cornerstone Planning Group LLC grew its position in Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock valued at $26,000 after acquiring an additional 48 shares in the last quarter. Hoey Investments Inc. acquired a new position in shares of Cencora during the first quarter worth about $28,000. Costello Asset Management INC acquired a new position in shares of Cencora during the first quarter worth about $28,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Cencora during the first quarter worth about $39,000. Finally, Vermillion Wealth Management Inc. acquired a new position in shares of Cencora during the fourth quarter worth about $38,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Performance

Shares of COR opened at $302.83 on Friday. The stock has a 50 day moving average price of $293.24 and a 200 day moving average price of $285.50. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The company has a market capitalization of $58.71 billion, a price-to-earnings ratio of 31.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. Cencora, Inc. has a 52-week low of $218.65 and a 52-week high of $309.35.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the company posted $3.34 earnings per share. Research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora’s dividend payout ratio is 22.63%.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 4,968 shares of the company’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the completion of the transaction, the chief executive officer directly owned 42,351 shares of the company’s stock, valued at $12,455,852.61. This represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the company’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the completion of the transaction, the chairman directly owned 311,913 shares of the company’s stock, valued at $91,271,982.06. This trade represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,125 shares of company stock valued at $9,993,789 over the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Morgan Stanley set a $330.00 price objective on Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Jefferies Financial Group boosted their price objective on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Finally, Wells Fargo & Company boosted their price objective on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $311.25.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.